Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab

Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab

Bevacizumab exerts anti-angiogenic effects in cancer patients by inhibiting vascular endothelial growth factor (VEGF). However, its use is still limited due to the development of resistance to the treatment. Such resistance can be regulated by various factors, although the underlying mechanisms rema...

Full description

Bibliographic Details
Main Authors: Mitsuhashi, Atsushi, Goto, Hisatsugu, Saijo, Atsuro, Trung, Van The, Aono, Yoshinori, Ogino, Hirokazu, Kuramoto, Takuya, Tabata, Sho, Uehara, Hisanori, Izumi, Keisuke, Yoshida, Mitsuteru, Kobayashi, Hiroaki, Takahashi, Hidefusa, Gotoh, Masashi, Kakiuchi, Soji, Hanibuchi, Masaki, Yano, Seiji, Yokomise, Hiroyasu, Sakiyama, Shoji, Nishioka, Yasuhiko
Format: Online
Language:English
Published: Nature Publishing Group 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686833/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686833/

Similar Items